| 1 |
Wang N, Huang X, Cheng J. Identification of the function, immunological role and m6A modification of MYSM1 in head and neck squamous cell carcinoma.. [DOI: 10.21203/rs.3.rs-1734482/v1] [Reference Citation Analysis]
|
| 2 |
Jiang J, Huang H, Chen R, Lin Y, Ling Q. Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors? Front Immunol 2023;14:1092401. [PMID: 36875077 DOI: 10.3389/fimmu.2023.1092401] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Cao W, Lu J, Li S, Song F, Xu J. Transcriptomic analysis of graft liver provides insight into the immune response of rat liver transplantation. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.947437] [Reference Citation Analysis]
|
| 4 |
Hu B, Qu C, Qi W, Liu C, Xiu D. Development and verification of the glycolysis-associated and immune-related prognosis signature for hepatocellular carcinoma. Front Genet 2022;13:955673. [DOI: 10.3389/fgene.2022.955673] [Reference Citation Analysis]
|
| 5 |
Huang AC, Dodge JL, Yao FY, Mehta N. National Experience on Waitlist Outcomes for Down-Staging of Hepatocellular Carcinoma: High Dropout Rate in All-Comers. Clin Gastroenterol Hepatol 2022:S1542-3565(22)00819-9. [PMID: 36038129 DOI: 10.1016/j.cgh.2022.08.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Wu J, Huang J, Zhu J, He Z, Chen M, Gao S, Liang D, Yu X, Lu C. Immune checkpoint inhibitors increase the risk of kidney transplant rejection: a real-world pharmacovigilance study. Expert Opin Drug Saf 2022. [PMID: 35929998 DOI: 10.1080/14740338.2022.2110234] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 7 |
Vulasala SSR, Onteddu NK, Kumar SP, Lall C, Bhosale P, Virarkar MK. Advances and effectiveness of the immunotherapy after liver transplantation. World J Gastrointest Surg 2022; 14(6): 629-631 [DOI: 10.4240/wjgs.v14.i6.629] [Reference Citation Analysis]
|
| 8 |
Azhie A, Grant RC, Herman M, Wang L, Knox JJ, Bhat M. Phase II clinical trial of cabozantinib for the treatment of recurrent hepatocellular carcinoma after liver transplantation. Future Oncol 2022. [PMID: 35287469 DOI: 10.2217/fon-2021-1635] [Reference Citation Analysis]
|
| 9 |
Zhang G, Su L, Lv X, Yang Q. A novel tumor doubling time-related immune gene signature for prognosis prediction in hepatocellular carcinoma. Cancer Cell Int 2021;21:522. [PMID: 34627241 DOI: 10.1186/s12935-021-02227-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 10 |
D'Alessio A, Cammarota A, Prete MG, Pressiani T, Rimassa L. The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together. Curr Opin Oncol 2021;33:386-94. [PMID: 33867478 DOI: 10.1097/CCO.0000000000000744] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 11 |
Hafezi M, Lin M, Chia A, Chua A, Ho ZZ, Fam R, Tan D, Aw J, Pavesi A, Krishnamoorthy TL, Chow WC, Chen W, Zhang Q, Wai LE, Koh S, Tan AT, Bertoletti A. Immunosuppressive Drug-Resistant Armored T-Cell Receptor T Cells for Immune Therapy of HCC in Liver Transplant Patients. Hepatology 2021;74:200-13. [PMID: 33249625 DOI: 10.1002/hep.31662] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 12 |
Rzeniewicz K, Larkin J, Menzies AM, Turajlic S. Immunotherapy use outside clinical trial populations: never say never? Ann Oncol 2021;32:866-80. [PMID: 33771665 DOI: 10.1016/j.annonc.2021.03.199] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 13 |
Chen GH, Wang GB, Huang F, Qin R, Yu XJ, Wu RL, Hou LJ, Ye ZH, Zhang XH, Zhao HC. Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period. Transpl Immunol. 2021;66:101386. [PMID: 33744409 DOI: 10.1016/j.trim.2021.101386] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 14 |
Bittner A, Radke J, Eurich D, Wiener E, Denker S, Anagnostopoulos I, Na IK, Heppner FL, Bullinger L, Schmitt CA. Cerebral EBV-positive PTLD controlled by PD-1 checkpoint blockade in a liver transplant patient. Leuk Lymphoma 2021;62:2026-9. [PMID: 33612072 DOI: 10.1080/10428194.2021.1889537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 15 |
Kondo T, Kawachi S, Nakatsugawa M, Takeda A, Kikawada N, Aihara Y, Okimura A, Hirano H, Ogawa Y, Tsukahara K. Nivolumab for recurrent/metastatic hypopharyngeal squamous cell carcinoma in a liver transplant recipient. Auris Nasus Larynx 2021:S0385-8146(21)00057-2. [PMID: 33612350 DOI: 10.1016/j.anl.2021.02.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 16 |
Braun M, Fuchs V, Kian W, Roisman L, Peled N, Rosenberg E, Friedel L. Nivolumab Induced Hepatocanalicular Cholestasis and Liver Rejection in a Patient With Lung Cancer and Liver Transplant. J Thorac Oncol 2020;15:e149-50. [PMID: 32854914 DOI: 10.1016/j.jtho.2020.01.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 17 |
Souquet P, Darrason M, Fontaine-delaruelle C, Freymond N. Existent-ils des contre-indications à l’immunothérapie dans les cancers broncho-pulmonaires ? Revue des Maladies Respiratoires Actualités 2020;12:2S373-2S377. [DOI: 10.1016/s1877-1203(20)30154-3] [Reference Citation Analysis]
|
| 18 |
Hu B, Yang XB, Sang XT. Development and Verification of the Hypoxia-Related and Immune-Associated Prognosis Signature for Hepatocellular Carcinoma. J Hepatocell Carcinoma 2020;7:315-30. [PMID: 33204664 DOI: 10.2147/JHC.S272109] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 19 |
Hu B, Yang XB, Sang XT. Molecular subtypes based on immune-related genes predict the prognosis for hepatocellular carcinoma patients. Int Immunopharmacol 2021;90:107164. [PMID: 33172741 DOI: 10.1016/j.intimp.2020.107164] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 20 |
Zhou K, Mehta N. Downstaging to Liver Transplant: Success Involves Choosing the Right Patient. Clin Liver Dis 2020;24:665-79. [PMID: 33012452 DOI: 10.1016/j.cld.2020.07.005] [Reference Citation Analysis]
|
| 21 |
Hu B, Yang XB, Sang XT. Construction of a lipid metabolism-related and immune-associated prognostic signature for hepatocellular carcinoma. Cancer Med 2020;9:7646-62. [PMID: 32813933 DOI: 10.1002/cam4.3353] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 22 |
Hu B, Lin JZ, Yang XB, Sang XT. The roles of mutated SWI/SNF complexes in the initiation and development of hepatocellular carcinoma and its regulatory effect on the immune system: A review. Cell Prolif 2020;53:e12791. [PMID: 32162380 DOI: 10.1111/cpr.12791] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 23 |
Vibert E, Schwartz M, Olthoff KM. Advances in resection and transplantation for hepatocellular carcinoma. J Hepatol 2020;72:262-76. [PMID: 31954491 DOI: 10.1016/j.jhep.2019.11.017] [Cited by in Crossref: 64] [Cited by in F6Publishing: 68] [Article Influence: 21.3] [Reference Citation Analysis]
|
